Clinical studies recruiting near Farmington Hills

Studies with at least one listed site matching this location on the public registry. Each page explains the study in plain language, with locations and study-team contacts. Clinicians: generate a printable list for your patient →

Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small C
Phase 3 · Michigan Healthcare Professionals Farmington · NRG Oncology · NCT05624996 Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease
Phase 2/Phase 3 · NRG Oncology · NCT05174169 Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SL
Phase 3 · National Cancer Institute (NCI) · NCT04269902 Collection of Research Data and Samples From Patients Who Experience Immunotherapy Side Effects
Phase N/A · Alliance for Clinical Trials in Oncology · NCT04242095 Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carci
Phase 3 · Weisberg Cancer Treatment Center · National Cancer Institute (NCI) · NCT05256225 Improving Adolescent and Young Adult Self-Reported Data in ECOG-ACRIN Trials
NA · Eastern Cooperative Oncology Group · NCT05108298 Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectab
Phase 2 · Corewell Health Farmington Hills Hospital · NRG Oncology · NCT05327686 Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
Phase 3 · ECOG-ACRIN Cancer Research Group · NCT04566328 De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Eq
Phase 3 · Michigan Healthcare Professionals Farmington · NRG Oncology · NCT04852887 Myopenia and Mechanisms of Chemotherapy Toxicity in Older Adults With Colorectal Cancer
Phase N/A · Wake Forest University Health Sciences · NCT03998202 mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Neg
Phase 3 · Weisberg Cancer Treatment Center · Alliance for Clinical Trials in Oncology · NCT05677490 Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide,
Phase 3 · Weisberg Cancer Treatment Center · National Cancer Institute (NCI) · NCT06058377 A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V60
Phase 2 · SWOG Cancer Research Network · NCT04511013 Comparing the Clinical Impact of Pancreatic Cyst Surveillance Programs and Associated Biomarkers
Phase N/A · Corewell Health Farmington Hills Hospital · ECOG-ACRIN Cancer Research Group · NCT04239573 Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Remo
Phase 2/Phase 3 · Weisberg Cancer Treatment Center · National Cancer Institute (NCI) · NCT05987241 Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The Co
Phase 2 · Corewell Health Farmington Hills Hospital · National Cancer Institute (NCI) · NCT05564377 Ramucirumab and Paclitaxel or FOLFIRI in Advanced Small Bowel Cancers
Phase 2 · Weisberg Cancer Treatment Center · SWOG Cancer Research Network · NCT04205968 A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab
Phase 3 · Weisberg Cancer Treatment Center · National Cancer Institute (NCI) · NCT05675410 Testing the Use of Neratinib or the Combination of Neratinib and Palbociclib Targeted Treatment for HER2+ Solid Tumors (
Phase 2 · Corewell Health Farmington Hills Hospital · National Cancer Institute (NCI) · NCT06126276 Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging
Phase 3 · ECOG-ACRIN Cancer Research Group · NCT04423211 Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head
Phase 2 · Weisberg Cancer Treatment Center · ECOG-ACRIN Cancer Research Group · NCT02734537 Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had
Phase 2/Phase 3 · SWOG Cancer Research Network · NCT06616584 Evaluating the Impact of Social and Genetic Factors on Outcomes in Adolescent and Young Adult Cancer Survivors
Phase N/A · ECOG-ACRIN Cancer Research Group · NCT06002828 S1703 Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic
NA · SWOG Cancer Research Network · NCT03723928 Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabo
Phase 2 · National Cancer Institute (NCI) · NCT03866382 Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung
Phase 3 · Corewell Health Farmington Hills Hospital · National Cancer Institute (NCI) · NCT04267848 A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participant
Phase 3 · AbbVie · NCT05889182 Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma
Phase 3 · ECOG-ACRIN Cancer Research Group · NCT03937635 Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer
Phase 2/Phase 3 · SWOG Cancer Research Network · NCT03851445 Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance C
Phase 3 · National Cancer Institute (NCI) · NCT07061977

Look up another city

Look up another condition